Women with rapidly lethal ovarian cancer are more likely to harbor tumors lacking a normal complement of two enzymes that facilitate the silencing of genes, a new study shows. Meanwhile, patients who survive significantly longer tend to have ample supplies of both compounds, scientists report in the Dec. 18 New England Journal of Medicine.

Data on patients with other cancers also linked better survival to adequate levels of one of these enzymes, the researchers find

If confirmed, the